¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
¼¼°èÀÇ ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀåÀº 2025³â¿¡ 2,322¾ï 8,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 4,500¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â¿¡ CAGR 9.9%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
º¸°í¼ ¹üÀ§ |
º¸°í¼ »ó¼¼ ³»¿ë |
±âÁØ¿¬µµ |
2024³â |
2025³â ½ÃÀå ±Ô¸ð |
2,322¾ï 8,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ |
2020-2024³â |
¿¹Ãø ±â°£ |
2025-2032³â |
¿¹Ãø ±â°£ : 2025-2032³â CAGR |
9.90% |
2032³â ±Ý¾× ¿¹Ãø |
4,500¾ï 7,000¸¸ ´Þ·¯ |
µµÇ¥. ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀå Áö¿ªº° Á¡À¯À²(%)(2025³â)

¼¼°è ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀåÀº Áö³ ¼ö³â°£ ²ÙÁØÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀǾàǰ ¼öŹÁ¦Á¶Àº ÀǾàǰÀÇ Á¦Á¶, Æ÷Àå, °Ë»ç µî ƯÁ¤ ÀǾàǰ °øÁ¤À» ÀǾàǰ ¼öŹÁ¦Á¶±â°ü(CMO)À¸·Î ¾Ë·ÁÁø Á¦3ÀÚ ±â¾÷¿¡ ¾Æ¿ô¼Ò½ÌÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. Á¦Á¶ ºñ¿ëÀ» Àý°¨Çϰí ÇÙ½É ¿ª·®¿¡ ÁýÁßÇØ¾ß ÇÒ Çʿ伺ÀÌ Ä¿Áö¸é¼ Á¦¾à»çµéÀÌ Á¦Á¶ ¿ä°ÇÀ» CMO¿¡ ¾Æ¿ô¼Ò½ÌÇÏ´Â ÁÖ¿ä ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Æ¯Çã ¸¸·á·Î ÀÎÇÑ Áö¼ÓÀûÀÎ ¼Õ½Ç, Á¦³×¸¯ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀǾàǰ °³¹ß ¹× »ó¾÷È È°µ¿ÀÇ ¾Æ¿ô¼Ò½Ì Áõ°¡ µîÀº ÇâÈÄ ¼ö³â°£ ¼¼°è ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
½ÃÀå ¿ªÇÐ
¼¼°è ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇÏ´Â °ÍÀº ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ºÎÁ¤¸Æ À§ÇèÀÌ ³ôÀº ³ë³âÃþ Àα¸ Áõ°¡ÀÔ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO) ÀÚ·á¿¡ µû¸£¸é ½ÉÇ÷°ü ÁúȯÀº Àü ¼¼°è »ç¸Á ¿øÀÎ 1À§·Î ¸Å³â 1,700¸¸ ¸í ÀÌ»óÀÌ ½ÉÀ帶ºñ¿Í ³úÁ¹ÁßÀ¸·Î ÀÎÇØ ¸ñ¼ûÀ» ÀÒ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼ÒÇüÈ¿Í ¹èÅ͸® ¼ö¸í ¿¬Àå¿¡ ÃÊÁ¡À» ¸ÂÃá ±â¼ú Çõ½ÅÀ¸·Î ½É¹ÚÁ¶À²±â À̽ÄÀÇ ÀûÀÀÁõÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ½É¹ÚÁ¶À²±â ¼ö¼ú¿¡ µû¸¥ ³ôÀº ºñ¿ë°ú ¸®µå °áÇÔ ¹× °¨¿°°ú °°Àº ±â±â ÇÕº´Áõ À§ÇèÀº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
- ¼¼°èÀÇ ÀǾàǰ ¼öŹÁ¦Á¶(CMO) ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
- ÀÌ º¸°í¼´Â ´Ù¾çÇÑ ºÎ¹®¿¡¼ ÀáÀçÀûÀÎ ¸ÅÃâ ¼ºÀå ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
- ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ ÁÖ¿ä ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
- ÀÌ º¸°í¼´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
- ÁÖ¿ä ±â¾÷¿¡´Â Lonza Group, Boehringer Ingelheim GmbH, Genpact Limited, Accenture plc, Quintiles Transnational Corporation, Baxter, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma, Pfizer, Inc., The Almac Group, Teva Pharmaceutical Industries Ltd., Piramal Enterprises Ltd., Covance, Inc., Catalent, Inc., Abbvie, Inc., Celltrion µîÀÌ Æ÷ÇԵ˴ϴÙ.
- ÀÌ º¸°í¼ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
- ¼¼°è ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀåÀº ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
- ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç
Á¦2Àå ½ÃÀå Àü¸Á
- ¸®Æ÷Æ® ¼³¸í
- °³¿ä
- COM(Coherent Opportunity Map)
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®
- ½ÃÀå ¿ªÇÐ
- ¿µÇ⠺м®
- ½ÃÀå µ¿Çâ
- ±ÔÁ¦ ½Ã³ª¸®¿À
- Àμö¿Í Á¦ÈÞ ½Ã³ª¸®¿À
- ÀÚ±ÝÁ¶´Þ°ú ÅõÀÚ
- PEST ºÐ¼®
- PorterÀÇ »ê¾÷ ºÐ¼®
Á¦4Àå ¼¼°èÀÇ ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ
- ÀüüÀûÀÎ ¿µÇâ
- Á¤ºÎ ±¸»ó
- ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ
Á¦5Àå ¼¼°èÀÇ ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀå, ¼ºñ½º À¯Çüº°, 2020-2032³â(10¾ï ´Þ·¯)
- ¼·Ð
- °è¾à Á¦Á¶ Á¶Á÷(CMO)
- API Á¦Á¶
- ÃÖÁ¾Á¦Çü Á¦Á¶
- Æ÷Àå
- ÀÓ»ó½ÃÇè¼öʱâ°ü(CRO)
- Drug Discovery
- ÀüÀÓ»ó ¿¬±¸
- Ãʱ⠴ܰè I-IIa
- ´Ü°è IIa-III
- ´Ü°è IIIb-IV
- ÀÇ·á ÄÚµù°ú ¶óÀÌÆÃ
- ¸ð´ÏÅ͸µ
- ÀÓ»ó µ¥ÀÌÅÍ °ü¸®
- ±âŸ(ÇÁ·ÎÅäÄÝ °³¹ß µî)
Á¦6Àå ¼¼°èÀÇ ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀå, ºÐÀÚ À¯Çüº°, 2020-2032³â(10¾ï ´Þ·¯)
Á¦7Àå ¼¼°èÀÇ ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀå, Áö¿ªº°, 2020-2032³â(10¾ï ´Þ·¯)
- ¼·Ð
- ºÏ¹Ì
- ¶óƾ¾Æ¸Þ¸®Ä«
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- 秵- ¾ÆÇÁ¸®Ä«
Á¦8Àå °æÀï ±¸µµ
- ±â¾÷ °³¿ä
- Lonza Group
- Boehringer Ingelheim GmbH
- Genpact Limited
- Accenture plc
- Quintiles Transnational Corporation
- Baxter
- Dr. Reddy's Laboratories Ltd.
- Aurobindo Pharma
- Pfizer, Inc.
- The Almac Group
- Teva Pharmaceutical Industries Ltd.
- Piramal Enterprises Ltd.
- Covance, Inc.
- Catalent, Inc.
- Abbvie, Inc.
- Celltrion
Á¦9Àå ¾Ö³Î¸®½ºÆ®ÀÇ ±ÇÀå»çÇ×
- ¿î¸íÀÇ ¼ö·¹¹ÙÄû
- COM(Coherent Opportunity Map)
Á¦10Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý
KSA 25.04.03
Global Contract Pharmaceutical Manufacturing Market is estimated to be valued at USD 232.28 Bn in 2025 and is expected to reach USD 450.07 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.9% from 2025 to 2032.
Report Coverage |
Report Details |
Base Year: |
2024 |
Market Size in 2025: |
USD 232.28 Bn |
Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: |
9.90% |
2032 Value Projection: |
USD 450.07 Bn |
Figure. Contract Pharmaceutical Manufacturing Market Share (%), By Region 2025

The global contract pharmaceutical manufacturing market has been witnessing steady growth over the past few years. Contract pharmaceutical manufacturing refers to the outsourcing of certain pharmaceutical processes such as manufacturing, packaging, and testing of pharmaceutical drugs to a third party company known as contract manufacturing organizations (CMOs). The growing need to reduce manufacturing costs and focus on core competencies are some of the key factors driving pharmaceutical companies to outsource their production requirements to CMOs. In addition, continued patent cliff losses, rising demand for generic drugs, and increasing outsourcing of drug development and commercialization activities are further expected to support the growth of the global contract pharmaceutical manufacturing market in the coming years.
Market Dynamics:
The global contract pharmaceutical manufacturing market growth is driven by rising incidence of cardiovascular diseases and increasing elderly population base globally who are at high risk of arrhythmias. According to the data by World Health Organization, cardiovascular diseases are the leading cause of deaths worldwide with over 17 million lives lost each year due to heart attacks and strokes. Moreover, technological innovations with focus on miniaturization and battery longevity have expanded indications for pacemaker implants. However, high costs associated with pacemaker procedures and risk of device complications such as lead defects and infections can hamper the market growth.
Key Features of the Study:
- This report provides an in-depth analysis of the global contract pharmaceutical manufacturing market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global contract pharmaceutical manufacturing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this includes Lonza Group, Boehringer Ingelheim GmbH, Genpact Limited, Accenture plc, Quintiles Transnational Corporation, Baxter , Dr. Reddy's Laboratories Ltd., Aurobindo Pharma, Pfizer, Inc., The Almac Group, Teva Pharmaceutical Industries Ltd., Piramal Enterprises Ltd., Covance, Inc., Catalent, Inc., Abbvie, Inc., and Celltrion.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global contract pharmaceutical manufacturing market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global contract pharmaceutical manufacturing market.
Detailed Segmentation-
- By Service Type:
- Contract Manufacturing Organization (CMO)
- API Manufacturing
- Final dosage form manufacturing
- Packaging
- Contract Research Organization (CRO)
- Drug Discovery
- Preclinical Studies
- Early Phase I - IIa
- Phase IIa - III
- Phase IIIb - IV
- Medical Coding and Writing
- Monitoring
- Clinical Data Management
- Others (Protocol Development, etc.)
- By Molecule Type:
- Small Molecule
- Large Molecule
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Lonza Group
- Boehringer Ingelheim GmbH
- Genpact Limited
- Accenture plc
- Quintiles Transnational Corporation
- Baxter
- Reddy's Laboratories Ltd.
- Aurobindo Pharma
- Pfizer, Inc.
- The Almac Group
- Teva Pharmaceutical Industries Ltd.
- Piramal Enterprises Ltd.
- Covance, Inc.
- Catalent, Inc.
- Abbvie, Inc.
- Celltrion
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Service Type
- Market Snapshot, By Molecule Type
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Contract Pharmaceutical Manufacturing Market - Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Contract Pharmaceutical Manufacturing Market, By Service Type, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Contract Manufacturing Organization (CMO)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- API Manufacturing
- Final dosage form manufacturing
- Packaging
- Contract Research Organization (CRO)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Drug Discovery
- Preclinical Studies
- Early Phase I - IIa
- Phase IIa - III
- Phase IIIb - IV
- Medical Coding and Writing
- Monitoring
- Clinical Data Management
- Others (Protocol Development, etc.)
6. Global Contract Pharmaceutical Manufacturing Market, By Molecule Type, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Small Molecule
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Large Molecule
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Contract Pharmaceutical Manufacturing Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Molecule Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Molecule Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Molecule Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Molecule Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Molecule Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Molecule Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Lonza Group
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boehringer Ingelheim GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Genpact Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Accenture plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Quintiles Transnational Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Baxter
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Aurobindo Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- The Almac Group
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Piramal Enterprises Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Covance, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Catalent, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Abbvie, Inc.
- Celltrion
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact